Navigation Links
TGen and Genomic Health Inc. discover genes affecting cancer drug

PHOENIX, Ariz. Jan. 13, 2011 Genomic research could help doctors better target a drug widely used to treat colorectal cancer patients, according to a study by Genomic Health Inc. (Nasdaq: GHDX) and the Translational Genomics Research Institute (TGen).

The drug, oxaliplatin, is widely used in colon cancer. It is used in early disease, following surgery in those cancers that are likely to recur. It is also used in advanced disease to slow progression of the cancer where it has spread to other parts of the body.

However, a significant number of patients experience serious side effects, including prolonged damage to the nervous system, "creating an urgent need to identify genes that are responsible for drug sensitivity or resistance, which results in directing therapy to those most likely to benefit," according to the study published in Molecular Cancer Research.

Colorectal cancer is the third most common type of cancer in the U.S., annually diagnosed in more than 146,000 Americans. It also is the third highest cause of cancer death in the U.S., annually killing nearly 50,000 people, more than who die each year on the nation's roadways. This cancer affects men and women in nearly equal numbers.

Nerve damage, or neurotoxicity, associated with oxaliplatin is most commonly manifest as pain or a loss of sensation in the hands and feet and can severely affect a patient's quality of life and ability to work. These symptoms are experienced in some form by the majority of patients receiving this drug and, for some patients, can be permanent.

The TGen/Genomic Health researchers examined the role of individual cancer genes to influence the sensitivity or resistance of colon cancer cells grown in laboratory culture. An interfering RNA screen of 500 genes with 2,000 unique siRNA sequences identified 27 genes that, when silenced, altered the sensitivity of colon tumor cells to oxaliplatin, causing damage to the cancer cells' DNA and inhibiting the cancer cells' ability to reproduce and survive, the study said. This study has also showed that diverse gene networks also play a role in the ability of the drug to impact colon tumors.

"These 27 genes, whose loss of function significantly affect the effectiveness of oxaliplatin, may be promising therapeutic biomarkers for oxaliplatin," said Dr. Holly Yin, head of TGen's Cellular Genomics Collaborative Center in Scottsdale, and a co-author of the study.

Dr. Robert J. Pelham, a research scientist at Redwood City, Calif.-based Genomic Health and the study's senior author, said the findings indicate a need for additional clinical studies on tumor specimens in patients treated with oxaliplatin. "Such future clinical studies could eventually lead to potential clinical applications, where patients could benefit," Dr. Pelham said.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related biology news :

1. Scientists decipher 3 billion-year-old genomic fossils
2. Reportlinker Adds Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
3. Genomic fault zones come and go
4. Salk Institute creates Renato Dulbecco Chair in Genomics and Roger Guillemin Chair in Neuroscience
5. Mississauga teacher awarded prize for excellence in teaching genomics
6. LSU researcher participates in NIH-funded study ushering in the age of personal genomics
7. Structural genomics accelerates protein structure determination
8. Genomic comparison of ocean microbes reveals East-West divide in populations
9. Structural Genomics Consortium releases 1,000th protein structure
10. Genomic haircut makes worlds tiniest genome even smaller: UBC research
11. NIH expands key pharmacogenomics resource
Post Your Comments:
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... October 29, 2015 NXTD ... company focused on the growing mobile commerce market ... that StackCommerce, a leading marketplace to discover and ... Wocket® smart wallet on StackSocial for this holiday ... or the "Company"), a biometric authentication company focused ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... HOLLISTON, Mass. , Nov. 30, 2015 /PRNewswire/ ... HART ), a biotechnology company developing bioengineered ... has received written notification from The NASDAQ Stock ... minimum bid price requirements. The letter noted that ... of HART,s common stock having exceeded $1.00 per ...
(Date:11/30/2015)... ... 30, 2015 , ... Imagine Exhibitions and Universal Partnerships & ... in March 2016 at Melbourne Museum in Melbourne, Australia. Immediately following the Australia ... tour dates. The Exhibition is based on Universal Pictures’ Jurassic World, one of ...
(Date:11/30/2015)... TapImmune, Inc. (TPIV), a ... peptide and gene-based immunotherapeutics and vaccines for the treatment ... be presenting at the 8 th Annual LD ... PM PT. Dr. John N. Bonfiglio a ... the presentation and will join TapImmune management in meeting ...
(Date:11/30/2015)... , Nov. 30, 2015  AbbVie, is introducing ... focuses on a daily routine for managing the life-long ... medication can affect the way the body absorbs it ... their a daily routine are important. The goal of ... patients better manage their hypothyroidism by establishing a daily ...
Breaking Biology Technology: